The Community of Castilla y León has notified the Spanish Agency for Medicines and Pharmaceutical Products (AEMPS) about two cases detected in Valladolid with possible adverse effects after receiving doses of the AstraZéneca-University of Oxford vaccine lot that is being analyzed by part of the European health authorities.
These are two patients treated at the Hospital Clínico Universitario de Valladolid, one with a diagnosis of non-infectious immunological encephalitis – which is stable, on the ward, and is progressing favorably – and the other with a stroke for which he was treated and has already received discharge.
The Hospital Clínico Universitario de Valladolid has applied the protocol established on a regular basis for this type of pathologies, with the aim of making a differential diagnosis and ruling out other etiologies of encephalitis, and determining -if possible- what the origin of the disease may be. .
We are waiting to know the results of the various tests requested -something that will take at least a week given its complexity-, so no specific cause-effect relationship can be established at this time.
The report has been sent within the framework established by the pharmacovigilance system for medicines for human use established by the Ministry of Health for the entire national territory in the event of this type of situation. As is known, in Spain there is a pharmacovigilance system to facilitate the collection of information on the adverse effects that drugs can cause. Any medicine can cause some unwanted side effect, which is called an ‘adverse drug reaction’ (ADR).
–
